Evaluation of S12363, a novel vinca alkaloid drug in the treatment of advanced malignant melanoma. A phase II study.
We conducted a phase II study with the new vinca alkaloid derivative S12363 in ten patients with metastatic malignant melanoma. Six patients had been pre-treated with other cytotoxic agents and all had received Vindesine. Four patients had no prior systemic treatment before entry into the study. S12363 was well tolerated subjectively, the main toxicity being haematological. Despite encouraging in vitro observations, no objective responses to S12363 have been documented in these patients with the doses and schedule used in this study. S12363 appears to have no clinically useful activity in metastatic malignant melanoma.
Stanley
A J
AJ
Medical Oncology Unit, Westminster Hospital, London, U.K.
Kaprielian
R
R
Retsas
S
S
D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D014748:Vinca Alkaloids / Q000627:therapeutic use*
D000972:Antineoplastic Agents, Phytogenic; D014748:Vinca Alkaloids; C064005:S 12363